Mestranol/hydroxyprogesterone acetate (ME/OHPA), sold under the brand name Hormolidin, is a combination medication of mestranol (ME), an estrogen, and hydroxyprogesterone acetate (OHPA), a progestin, which was reportedly used as a sequential combined birth control pill for women in the early 1970s.[1] It was formulated as oral tablets and contained 16 tablets of 80 μg ME, 5 tablets of 80 μg ME and 100 mg OHPA, and 7 placebo tablets (28 tablets in total).[1] The medication was manufactured by the pharmaceutical company Gador in Argentina.[1]
 | |
 | |
| Combination of | |
|---|---|
| Mestranol | Estrogen |
| Hydroxyprogesterone acetate | Progestogen |
| Clinical data | |
| Trade names | Hormolidin |
| Other names | ME/OHPA; EEME/OHPA |
| Routes of administration | By mouth |
| Drug class | Estrogen; Progestogen |
See also
editReferences
edit- ^ a b c Rudel HW, Kinel FA (September 1972). "Oral Contraceptives. Human Fertility Studies and Side Effects". In Tausk M (ed.). Pharmacology of the Endocrine System and Related Drugs: Progesterone, Progestational Drugs and Antifertility Agents. Vol. II. Pergamon Press. pp. 385–469. ISBN 978-0080168128. OCLC 278011135.
 | This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it. |